NCT02306785View on ClinicalTrials.gov

TP0502-Pharmaco-Scintigraphic-Study and Amendment

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

June 30, 2013

Conditions
Ulcerative Colitis
Interventions
DRUG

TP05 Coating D

One radio-labelled tablet given to subjects

DRUG

TP05 Coating E

One radio-labelled tablet given to subjects

DRUG

TP05 Coating H

One radio-labelled tablet given to subjects

All Listed Sponsors
lead

Tillotts Pharma AG

INDUSTRY

NCT02306785 - TP0502-Pharmaco-Scintigraphic-Study and Amendment | Biotech Hunter | Biotech Hunter